Form 4 for ANIP ANI PHARMACEUTICALS INC
Accepted 2025-08-14 00:00:00 ET · period of report 2025-08-12 · accession 0001507496-25-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-14 | 2025-08-12 | ANIP | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | S - Sale | $85.71 | -4,975 | 40.8K | -11% | -$426.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-12 | S | D | 4,975 | $85.71 | 40,794 | D | — | — | (F1) The shares were sold in multiple trades at prices ranging from $85.52 to $86.22. The price reported above reflects the weighted average sales price. (F2) Includes 304 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c). |